

Global Scleroderma Therapeutics Market Growth (Status and Outlook) 2025-2031

<https://marketpublishers.com/r/GB0F5897C7DEN.html>

Date: September 2025

Pages: 123

Price: US\$ 3,660.00 (Single User License)

ID: GB0F5897C7DEN

Abstracts

According to this study, the global Scleroderma Therapeutics market size will reach US\$ 1912 million by 2031.

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the "Scleroderma Therapeutics Industry Forecast" looks at past sales and reviews total world Scleroderma Therapeutics sales

in 2024, providing a comprehensive analysis by region and market sector of projected Scleroderma Therapeutics sales for 2025 through 2031. With Scleroderma Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Scleroderma Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Scleroderma Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Scleroderma Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Scleroderma Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Scleroderma Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Scleroderma Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Scleroderma Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:

Immunosuppressors

Phosphodiesterase 5 Inhibitors - PHA

Endothelin Receptor Antagonists

Prostacyclin Analogues

Calcium Channel Blockers

Analgesics

Others

Segmentation by Application:

Systemic

Localized

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

F. Hoffmann-La Roche AG

Bristol-Myers Squibb Company

Celgene Corporation

Argentis Pharmaceuticals, LLC

Bayer AG

Boehringer Ingelheim International GmbH

Akashi Therapeutics

Prometic Life Sciences, Inc.

Emerald Health Pharmaceuticals

Kadmon Holdings, Inc.

Seattle Genetics, Inc.

Cytori Therapeutics, Inc.

Fibrocell Science, Inc.

Chemomab

Corbus Pharmaceuticals Holdings, Inc.

Genkyotex

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Scleroderma Therapeutics Market Size (2020-2031)
 - 2.1.2 Scleroderma Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031)
 - 2.1.3 World Current & Future Analysis for Scleroderma Therapeutics by Country/Region (2020, 2024 & 2031)
- 2.2 Scleroderma Therapeutics Segment by Type
 - 2.2.1 Immunosuppressors
 - 2.2.2 Phosphodiesterase 5 Inhibitors - PHA
 - 2.2.3 Endothelin Receptor Antagonists
 - 2.2.4 Prostacyclin Analogues
 - 2.2.5 Calcium Channel Blockers
 - 2.2.6 Analgesics
 - 2.2.7 Others
- 2.3 Scleroderma Therapeutics Market Size by Type
 - 2.3.1 Scleroderma Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031)
 - 2.3.2 Global Scleroderma Therapeutics Market Size Market Share by Type (2020-2025)
- 2.4 Scleroderma Therapeutics Segment by Application
 - 2.4.1 Systemic
 - 2.4.2 Localized
- 2.5 Scleroderma Therapeutics Market Size by Application
 - 2.5.1 Scleroderma Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031)

2.5.2 Global Scleroderma Therapeutics Market Size Market Share by Application (2020-2025)

3 SCLERODERMA THERAPEUTICS MARKET SIZE BY PLAYER

3.1 Scleroderma Therapeutics Market Size Market Share by Player

3.1.1 Global Scleroderma Therapeutics Revenue by Player (2020-2025)

3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Player (2020-2025)

3.2 Global Scleroderma Therapeutics Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 SCLERODERMA THERAPEUTICS BY REGION

4.1 Scleroderma Therapeutics Market Size by Region (2020-2025)

4.2 Global Scleroderma Therapeutics Annual Revenue by Country/Region (2020-2025)

4.3 Americas Scleroderma Therapeutics Market Size Growth (2020-2025)

4.4 APAC Scleroderma Therapeutics Market Size Growth (2020-2025)

4.5 Europe Scleroderma Therapeutics Market Size Growth (2020-2025)

4.6 Middle East & Africa Scleroderma Therapeutics Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Scleroderma Therapeutics Market Size by Country (2020-2025)

5.2 Americas Scleroderma Therapeutics Market Size by Type (2020-2025)

5.3 Americas Scleroderma Therapeutics Market Size by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Scleroderma Therapeutics Market Size by Region (2020-2025)

6.2 APAC Scleroderma Therapeutics Market Size by Type (2020-2025)

6.3 APAC Scleroderma Therapeutics Market Size by Application (2020-2025)

- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Scleroderma Therapeutics Market Size by Country (2020-2025)
- 7.2 Europe Scleroderma Therapeutics Market Size by Type (2020-2025)
- 7.3 Europe Scleroderma Therapeutics Market Size by Application (2020-2025)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Scleroderma Therapeutics by Region (2020-2025)
- 8.2 Middle East & Africa Scleroderma Therapeutics Market Size by Type (2020-2025)
- 8.3 Middle East & Africa Scleroderma Therapeutics Market Size by Application (2020-2025)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL SCLERODERMA THERAPEUTICS MARKET FORECAST

- 10.1 Global Scleroderma Therapeutics Forecast by Region (2026-2031)

- 10.1.1 Global Scleroderma Therapeutics Forecast by Region (2026-2031)
- 10.1.2 Americas Scleroderma Therapeutics Forecast
- 10.1.3 APAC Scleroderma Therapeutics Forecast
- 10.1.4 Europe Scleroderma Therapeutics Forecast
- 10.1.5 Middle East & Africa Scleroderma Therapeutics Forecast
- 10.2 Americas Scleroderma Therapeutics Forecast by Country (2026-2031)
 - 10.2.1 United States Market Scleroderma Therapeutics Forecast
 - 10.2.2 Canada Market Scleroderma Therapeutics Forecast
 - 10.2.3 Mexico Market Scleroderma Therapeutics Forecast
 - 10.2.4 Brazil Market Scleroderma Therapeutics Forecast
- 10.3 APAC Scleroderma Therapeutics Forecast by Region (2026-2031)
 - 10.3.1 China Scleroderma Therapeutics Market Forecast
 - 10.3.2 Japan Market Scleroderma Therapeutics Forecast
 - 10.3.3 Korea Market Scleroderma Therapeutics Forecast
 - 10.3.4 Southeast Asia Market Scleroderma Therapeutics Forecast
 - 10.3.5 India Market Scleroderma Therapeutics Forecast
 - 10.3.6 Australia Market Scleroderma Therapeutics Forecast
- 10.4 Europe Scleroderma Therapeutics Forecast by Country (2026-2031)
 - 10.4.1 Germany Market Scleroderma Therapeutics Forecast
 - 10.4.2 France Market Scleroderma Therapeutics Forecast
 - 10.4.3 UK Market Scleroderma Therapeutics Forecast
 - 10.4.4 Italy Market Scleroderma Therapeutics Forecast
 - 10.4.5 Russia Market Scleroderma Therapeutics Forecast
- 10.5 Middle East & Africa Scleroderma Therapeutics Forecast by Region (2026-2031)
 - 10.5.1 Egypt Market Scleroderma Therapeutics Forecast
 - 10.5.2 South Africa Market Scleroderma Therapeutics Forecast
 - 10.5.3 Israel Market Scleroderma Therapeutics Forecast
 - 10.5.4 Turkey Market Scleroderma Therapeutics Forecast
- 10.6 Global Scleroderma Therapeutics Forecast by Type (2026-2031)
- 10.7 Global Scleroderma Therapeutics Forecast by Application (2026-2031)
 - 10.7.1 GCC Countries Market Scleroderma Therapeutics Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 F. Hoffmann-La Roche AG
 - 11.1.1 F. Hoffmann-La Roche AG Company Information
 - 11.1.2 F. Hoffmann-La Roche AG Scleroderma Therapeutics Product Offered
 - 11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)

- 11.1.4 F. Hoffmann-La Roche AG Main Business Overview
- 11.1.5 F. Hoffmann-La Roche AG Latest Developments
- 11.2 Bristol-Myers Squibb Company
 - 11.2.1 Bristol-Myers Squibb Company Company Information
 - 11.2.2 Bristol-Myers Squibb Company Scleroderma Therapeutics Product Offered
 - 11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.2.4 Bristol-Myers Squibb Company Main Business Overview
 - 11.2.5 Bristol-Myers Squibb Company Latest Developments
- 11.3 Celgene Corporation
 - 11.3.1 Celgene Corporation Company Information
 - 11.3.2 Celgene Corporation Scleroderma Therapeutics Product Offered
 - 11.3.3 Celgene Corporation Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.3.4 Celgene Corporation Main Business Overview
 - 11.3.5 Celgene Corporation Latest Developments
- 11.4 Argentis Pharmaceuticals, LLC
 - 11.4.1 Argentis Pharmaceuticals, LLC Company Information
 - 11.4.2 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Product Offered
 - 11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.4.4 Argentis Pharmaceuticals, LLC Main Business Overview
 - 11.4.5 Argentis Pharmaceuticals, LLC Latest Developments
- 11.5 Bayer AG
 - 11.5.1 Bayer AG Company Information
 - 11.5.2 Bayer AG Scleroderma Therapeutics Product Offered
 - 11.5.3 Bayer AG Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.5.4 Bayer AG Main Business Overview
 - 11.5.5 Bayer AG Latest Developments
- 11.6 Boehringer Ingelheim International GmbH
 - 11.6.1 Boehringer Ingelheim International GmbH Company Information
 - 11.6.2 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Product Offered
 - 11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.6.4 Boehringer Ingelheim International GmbH Main Business Overview
 - 11.6.5 Boehringer Ingelheim International GmbH Latest Developments
- 11.7 Akashi Therapeutics

- 11.7.1 Akashi Therapeutics Company Information
- 11.7.2 Akashi Therapeutics Scleroderma Therapeutics Product Offered
- 11.7.3 Akashi Therapeutics Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 11.7.4 Akashi Therapeutics Main Business Overview
- 11.7.5 Akashi Therapeutics Latest Developments
- 11.8 Prometic Life Sciences, Inc.
 - 11.8.1 Prometic Life Sciences, Inc. Company Information
 - 11.8.2 Prometic Life Sciences, Inc. Scleroderma Therapeutics Product Offered
 - 11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.8.4 Prometic Life Sciences, Inc. Main Business Overview
 - 11.8.5 Prometic Life Sciences, Inc. Latest Developments
- 11.9 Emerald Health Pharmaceuticals
 - 11.9.1 Emerald Health Pharmaceuticals Company Information
 - 11.9.2 Emerald Health Pharmaceuticals Scleroderma Therapeutics Product Offered
 - 11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.9.4 Emerald Health Pharmaceuticals Main Business Overview
 - 11.9.5 Emerald Health Pharmaceuticals Latest Developments
- 11.10 Kadmon Holdings, Inc.
 - 11.10.1 Kadmon Holdings, Inc. Company Information
 - 11.10.2 Kadmon Holdings, Inc. Scleroderma Therapeutics Product Offered
 - 11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.10.4 Kadmon Holdings, Inc. Main Business Overview
 - 11.10.5 Kadmon Holdings, Inc. Latest Developments
- 11.11 Seattle Genetics, Inc.
 - 11.11.1 Seattle Genetics, Inc. Company Information
 - 11.11.2 Seattle Genetics, Inc. Scleroderma Therapeutics Product Offered
 - 11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.11.4 Seattle Genetics, Inc. Main Business Overview
 - 11.11.5 Seattle Genetics, Inc. Latest Developments
- 11.12 Cytori Therapeutics, Inc.
 - 11.12.1 Cytori Therapeutics, Inc. Company Information
 - 11.12.2 Cytori Therapeutics, Inc. Scleroderma Therapeutics Product Offered
 - 11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)

- 11.12.4 Cytori Therapeutics, Inc. Main Business Overview
- 11.12.5 Cytori Therapeutics, Inc. Latest Developments
- 11.13 Fibrocell Science, Inc.
 - 11.13.1 Fibrocell Science, Inc. Company Information
 - 11.13.2 Fibrocell Science, Inc. Scleroderma Therapeutics Product Offered
 - 11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.13.4 Fibrocell Science, Inc. Main Business Overview
 - 11.13.5 Fibrocell Science, Inc. Latest Developments
- 11.14 Chemomab
 - 11.14.1 Chemomab Company Information
 - 11.14.2 Chemomab Scleroderma Therapeutics Product Offered
 - 11.14.3 Chemomab Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.14.4 Chemomab Main Business Overview
 - 11.14.5 Chemomab Latest Developments
- 11.15 Corbus Pharmaceuticals Holdings, Inc.
 - 11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Information
 - 11.15.2 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Product Offered
 - 11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.15.4 Corbus Pharmaceuticals Holdings, Inc. Main Business Overview
 - 11.15.5 Corbus Pharmaceuticals Holdings, Inc. Latest Developments
- 11.16 Genkyotex
 - 11.16.1 Genkyotex Company Information
 - 11.16.2 Genkyotex Scleroderma Therapeutics Product Offered
 - 11.16.3 Genkyotex Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
 - 11.16.4 Genkyotex Main Business Overview
 - 11.16.5 Genkyotex Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Scleroderma Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) & (\$ millions)

Table 2. Scleroderma Therapeutics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Immunosuppressors

Table 4. Major Players of Phosphodiesterase 5 Inhibitors - PHA

Table 5. Major Players of Endothelin Receptor Antagonists

Table 6. Major Players of Prostacyclin Analogues

Table 7. Major Players of Calcium Channel Blockers

Table 8. Major Players of Analgesics

Table 9. Major Players of Others

Table 10. Scleroderma Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031) & (\$ millions)

Table 11. Global Scleroderma Therapeutics Market Size by Type (2020-2025) & (\$ millions)

Table 12. Global Scleroderma Therapeutics Market Size Market Share by Type (2020-2025)

Table 13. Scleroderma Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) & (\$ millions)

Table 14. Global Scleroderma Therapeutics Market Size by Application (2020-2025) & (\$ millions)

Table 15. Global Scleroderma Therapeutics Market Size Market Share by Application (2020-2025)

Table 16. Global Scleroderma Therapeutics Revenue by Player (2020-2025) & (\$ millions)

Table 17. Global Scleroderma Therapeutics Revenue Market Share by Player (2020-2025)

Table 18. Scleroderma Therapeutics Key Players Head office and Products Offered

Table 19. Scleroderma Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 20. New Products and Potential Entrants

Table 21. Mergers & Acquisitions, Expansion

Table 22. Global Scleroderma Therapeutics Market Size by Region (2020-2025) & (\$ millions)

Table 23. Global Scleroderma Therapeutics Market Size Market Share by Region

(2020-2025)

Table 24. Global Scleroderma Therapeutics Revenue by Country/Region (2020-2025) & (\$ millions)

Table 25. Global Scleroderma Therapeutics Revenue Market Share by Country/Region (2020-2025)

Table 26. Americas Scleroderma Therapeutics Market Size by Country (2020-2025) & (\$ millions)

Table 27. Americas Scleroderma Therapeutics Market Size Market Share by Country (2020-2025)

Table 28. Americas Scleroderma Therapeutics Market Size by Type (2020-2025) & (\$ millions)

Table 29. Americas Scleroderma Therapeutics Market Size Market Share by Type (2020-2025)

Table 30. Americas Scleroderma Therapeutics Market Size by Application (2020-2025) & (\$ millions)

Table 31. Americas Scleroderma Therapeutics Market Size Market Share by Application (2020-2025)

Table 32. APAC Scleroderma Therapeutics Market Size by Region (2020-2025) & (\$ millions)

Table 33. APAC Scleroderma Therapeutics Market Size Market Share by Region (2020-2025)

Table 34. APAC Scleroderma Therapeutics Market Size by Type (2020-2025) & (\$ millions)

Table 35. APAC Scleroderma Therapeutics Market Size by Application (2020-2025) & (\$ millions)

Table 36. Europe Scleroderma Therapeutics Market Size by Country (2020-2025) & (\$ millions)

Table 37. Europe Scleroderma Therapeutics Market Size Market Share by Country (2020-2025)

Table 38. Europe Scleroderma Therapeutics Market Size by Type (2020-2025) & (\$ millions)

Table 39. Europe Scleroderma Therapeutics Market Size by Application (2020-2025) & (\$ millions)

Table 40. Middle East & Africa Scleroderma Therapeutics Market Size by Region (2020-2025) & (\$ millions)

Table 41. Middle East & Africa Scleroderma Therapeutics Market Size by Type (2020-2025) & (\$ millions)

Table 42. Middle East & Africa Scleroderma Therapeutics Market Size by Application (2020-2025) & (\$ millions)

Table 43. Key Market Drivers & Growth Opportunities of Scleroderma Therapeutics

Table 44. Key Market Challenges & Risks of Scleroderma Therapeutics

Table 45. Key Industry Trends of Scleroderma Therapeutics

Table 46. Global Scleroderma Therapeutics Market Size Forecast by Region
(2026-2031) & (\$ millions)

Table 47. Global Scleroderma Therapeutics Market Size Market Share Forecast by
Region (2026-2031)

Table 48. Global Scleroderma Therapeutics Market Size Forecast by Type (2026-2031)
& (\$ millions)

Table 49. Global Scleroderma Therapeutics Market Size Forecast by Application
(2026-2031) & (\$ millions)

Table 50. F. Hoffmann-La Roche AG Details, Company Type, Scleroderma
Therapeutics Area Served and Its Competitors

Table 51. F. Hoffmann-La Roche AG Scleroderma Therapeutics Product Offered

Table 52. F. Hoffmann-La Roche AG Scleroderma Therapeutics Revenue (\$ million),
Gross Margin and Market Share (2020-2025)

Table 53. F. Hoffmann-La Roche AG Main Business

Table 54. F. Hoffmann-La Roche AG Latest Developments

Table 55. Bristol-Myers Squibb Company Details, Company Type, Scleroderma
Therapeutics Area Served and Its Competitors

Table 56. Bristol-Myers Squibb Company Scleroderma Therapeutics Product Offered

Table 57. Bristol-Myers Squibb Company Scleroderma Therapeutics Revenue (\$
million), Gross Margin and Market Share (2020-2025)

Table 58. Bristol-Myers Squibb Company Main Business

Table 59. Bristol-Myers Squibb Company Latest Developments

Table 60. Celgene Corporation Details, Company Type, Scleroderma Therapeutics
Area Served and Its Competitors

Table 61. Celgene Corporation Scleroderma Therapeutics Product Offered

Table 62. Celgene Corporation Scleroderma Therapeutics Revenue (\$ million), Gross
Margin and Market Share (2020-2025)

Table 63. Celgene Corporation Main Business

Table 64. Celgene Corporation Latest Developments

Table 65. Argentis Pharmaceuticals, LLC Details, Company Type, Scleroderma
Therapeutics Area Served and Its Competitors

Table 66. Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Product Offered

Table 67. Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Revenue (\$
million), Gross Margin and Market Share (2020-2025)

Table 68. Argentis Pharmaceuticals, LLC Main Business

Table 69. Argentis Pharmaceuticals, LLC Latest Developments

Table 70. Bayer AG Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 71. Bayer AG Scleroderma Therapeutics Product Offered

Table 72. Bayer AG Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 73. Bayer AG Main Business

Table 74. Bayer AG Latest Developments

Table 75. Boehringer Ingelheim International GmbH Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 76. Boehringer Ingelheim International GmbH Scleroderma Therapeutics Product Offered

Table 77. Boehringer Ingelheim International GmbH Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 78. Boehringer Ingelheim International GmbH Main Business

Table 79. Boehringer Ingelheim International GmbH Latest Developments

Table 80. Akashi Therapeutics Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 81. Akashi Therapeutics Scleroderma Therapeutics Product Offered

Table 82. Akashi Therapeutics Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 83. Akashi Therapeutics Main Business

Table 84. Akashi Therapeutics Latest Developments

Table 85. Prometic Life Sciences, Inc. Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 86. Prometic Life Sciences, Inc. Scleroderma Therapeutics Product Offered

Table 87. Prometic Life Sciences, Inc. Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 88. Prometic Life Sciences, Inc. Main Business

Table 89. Prometic Life Sciences, Inc. Latest Developments

Table 90. Emerald Health Pharmaceuticals Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 91. Emerald Health Pharmaceuticals Scleroderma Therapeutics Product Offered

Table 92. Emerald Health Pharmaceuticals Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 93. Emerald Health Pharmaceuticals Main Business

Table 94. Emerald Health Pharmaceuticals Latest Developments

Table 95. Kadmon Holdings, Inc. Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 96. Kadmon Holdings, Inc. Scleroderma Therapeutics Product Offered

Table 97. Kadmon Holdings, Inc. Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 98. Kadmon Holdings, Inc. Main Business

Table 99. Kadmon Holdings, Inc. Latest Developments

Table 100. Seattle Genetics, Inc. Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 101. Seattle Genetics, Inc. Scleroderma Therapeutics Product Offered

Table 102. Seattle Genetics, Inc. Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 103. Seattle Genetics, Inc. Main Business

Table 104. Seattle Genetics, Inc. Latest Developments

Table 105. Cytori Therapeutics, Inc. Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 106. Cytori Therapeutics, Inc. Scleroderma Therapeutics Product Offered

Table 107. Cytori Therapeutics, Inc. Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 108. Cytori Therapeutics, Inc. Main Business

Table 109. Cytori Therapeutics, Inc. Latest Developments

Table 110. Fibrocell Science, Inc. Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 111. Fibrocell Science, Inc. Scleroderma Therapeutics Product Offered

Table 112. Fibrocell Science, Inc. Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 113. Fibrocell Science, Inc. Main Business

Table 114. Fibrocell Science, Inc. Latest Developments

Table 115. Chemomab Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 116. Chemomab Scleroderma Therapeutics Product Offered

Table 117. Chemomab Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 118. Chemomab Main Business

Table 119. Chemomab Latest Developments

Table 120. Corbus Pharmaceuticals Holdings, Inc. Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 121. Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Product Offered

Table 122. Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 123. Corbus Pharmaceuticals Holdings, Inc. Main Business

Table 124. Corbus Pharmaceuticals Holdings, Inc. Latest Developments

Table 125. Genkyotex Details, Company Type, Scleroderma Therapeutics Area Served and Its Competitors

Table 126. Genkyotex Scleroderma Therapeutics Product Offered

Table 127. Genkyotex Scleroderma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 128. Genkyotex Main Business

Table 129. Genkyotex Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Scleroderma Therapeutics Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Scleroderma Therapeutics Market Size Growth Rate (2020-2031) (\$ millions)

Figure 6. Scleroderma Therapeutics Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 7. Scleroderma Therapeutics Sales Market Share by Country/Region (2024)

Figure 8. Scleroderma Therapeutics Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 9. Global Scleroderma Therapeutics Market Size Market Share by Type in 2024

Figure 10. Scleroderma Therapeutics in Systemic

Figure 11. Global Scleroderma Therapeutics Market: Systemic (2020-2025) & (\$ millions)

Figure 12. Scleroderma Therapeutics in Localized

Figure 13. Global Scleroderma Therapeutics Market: Localized (2020-2025) & (\$ millions)

Figure 14. Global Scleroderma Therapeutics Market Size Market Share by Application in 2024

Figure 15. Global Scleroderma Therapeutics Revenue Market Share by Player in 2024

Figure 16. Global Scleroderma Therapeutics Market Size Market Share by Region (2020-2025)

Figure 17. Americas Scleroderma Therapeutics Market Size 2020-2025 (\$ millions)

Figure 18. APAC Scleroderma Therapeutics Market Size 2020-2025 (\$ millions)

Figure 19. Europe Scleroderma Therapeutics Market Size 2020-2025 (\$ millions)

Figure 20. Middle East & Africa Scleroderma Therapeutics Market Size 2020-2025 (\$ millions)

Figure 21. Americas Scleroderma Therapeutics Value Market Share by Country in 2024

Figure 22. United States Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 23. Canada Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 24. Mexico Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 25. Brazil Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 26. APAC Scleroderma Therapeutics Market Size Market Share by Region in 2024

Figure 27. APAC Scleroderma Therapeutics Market Size Market Share by Type (2020-2025)

Figure 28. APAC Scleroderma Therapeutics Market Size Market Share by Application (2020-2025)

Figure 29. China Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 30. Japan Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 31. South Korea Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 32. Southeast Asia Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 33. India Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 34. Australia Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 35. Europe Scleroderma Therapeutics Market Size Market Share by Country in 2024

Figure 36. Europe Scleroderma Therapeutics Market Size Market Share by Type (2020-2025)

Figure 37. Europe Scleroderma Therapeutics Market Size Market Share by Application (2020-2025)

Figure 38. Germany Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 39. France Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 40. UK Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 41. Italy Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 42. Russia Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 43. Middle East & Africa Scleroderma Therapeutics Market Size Market Share by Region (2020-2025)

Figure 44. Middle East & Africa Scleroderma Therapeutics Market Size Market Share by Type (2020-2025)

Figure 45. Middle East & Africa Scleroderma Therapeutics Market Size Market Share by Application (2020-2025)

Figure 46. Egypt Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 47. South Africa Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 48. Israel Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 49. Turkey Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 50. GCC Countries Scleroderma Therapeutics Market Size Growth 2020-2025 (\$ millions)

Figure 51. Americas Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 52. APAC Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 53. Europe Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 54. Middle East & Africa Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 55. United States Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 56. Canada Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 57. Mexico Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 58. Brazil Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 59. China Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 60. Japan Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 61. Korea Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 62. Southeast Asia Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 63. India Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 64. Australia Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 65. Germany Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 66. France Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 67. UK Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 68. Italy Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 69. Russia Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 70. Egypt Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 71. South Africa Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 72. Israel Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 73. Turkey Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

Figure 74. Global Scleroderma Therapeutics Market Size Market Share Forecast by Type (2026-2031)

Figure 75. Global Scleroderma Therapeutics Market Size Market Share Forecast by Application (2026-2031)

Figure 76. GCC Countries Scleroderma Therapeutics Market Size 2026-2031 (\$ millions)

I would like to order

Product name: Global Scleroderma Therapeutics Market Growth (Status and Outlook) 2025-2031

Product link: <https://marketpublishers.com/r/GB0F5897C7DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB0F5897C7DEN.html>